Coronary Stenting

  • Trevor SimardEmail author
  • Juan J. Russo
  • Edward R. O’Brien
  • Benjamin Hibbert


Use of coronary stents as luminal scaffolds and drug delivery systems has revolutionized percutaneous coronary intervention. From their initial role as a bailout for angioplasty complications, coronary stents have evolved into the standard of care for obstructive coronary artery disease. Although early interventions were met with challenges related to abrupt vessel closure and restenosis, later use of bare-metal stents faced challenges related primarily to neointima formation and subsequent in-stent restenosis. The advent of first-generation drug-eluting stents limited the development of neointima, but were linked to stent thrombosis as a result of impaired vessel healing, triggering the continued refinement of stent technology. We discuss the relevant pathophysiologies of neointima formation and stent thrombosis as they pertain to stent development. In particular, we highlight key advancements in coronary stent development, ranging from the refinement of early bare-metal stents to drug-eluting stents with ever-advancing generations of antiproliferative agents, biocompatible polymers, and stent designs. Last, we touch on novel strategies for coronary stenting, including bioresorbable scaffolds and polymers, bifurcation stents, covered stents, and endothelial progenitor cell capture stents.


  1. 1.
    Iqbal J, Gunn J, Serruys PW. Coronary stents: historical development, current status and future directions. Br Med Bull. 2013;106:193–211.PubMedCrossRefGoogle Scholar
  2. 2.
    Puel J, Joffre F, Rousseau H, Guermonprez JL, Lancelin B, Morice MC, et al. Self-expanding coronary endoprosthesis in the prevention of restenosis following transluminal angioplasty. Preliminary clinical study. Arch Mal Coeur Vaiss. 1987;80(8):1311–2.PubMedGoogle Scholar
  3. 3.
    Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316(12):701–6.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Garg S, Serruys PW. Coronary stents current status. J Am Coll Cardiol. 2010;56(10s1):S1–S42.PubMedCrossRefGoogle Scholar
  5. 5.
    Schmidt WL. In: Lanzer P, editor. Catheter-based cardiovascular interventions, knowledge-based approach. Berlin, Heidelberg, New York: Springer; 2013. p. 445–72.CrossRefGoogle Scholar
  6. 6.
    Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med. 1994;331(8):496–501.CrossRefPubMedGoogle Scholar
  7. 7.
    Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. N Engl J Med. 1994;331(8):489–95.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Pourdjabbar A, Hibbert B, Simard T, Ma X, O’ Brien ER. Pathogenesis of Neointima formation following vascular injury. Cardiovasc Haematol Disord Drug Targets(Formerly Current Drug Targets). 2011;11(1):30–9.CrossRefGoogle Scholar
  9. 9.
    Ogita M, Miyauchi K, Kurata T, Yokoyama K, Dohi T, Tuboi S, et al. Clinical impact of angiographic restenosis after bare-metal stent implantation on long-term outcomes in patients with coronary artery disease. Circ J. 2011;75(11):2566–72.PubMedCrossRefGoogle Scholar
  10. 10.
    Simard T, Hibbert B, Ramirez FD, Froeschl M, Chen YX, O'Brien ER. The evolution of coronary stents: a brief review. Can J Cardiol. 2014;30(1):35–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Schatz RA. A view of vascular stents. Circulation. 1989;79(2):445–57.PubMedCrossRefGoogle Scholar
  13. 13.
    Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ. Evaluation of the Medtronic (driver) cobalt-chromium alloy coronary stent system. Am J Cardiol. 2005;95(1):8–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Allocco DJ, Joshi AA, Dawkins KD. Everolimus-eluting stents: update on current clinical studies. Med Devices (Auckland). 2011;4:91–8.Google Scholar
  15. 15.
    Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED, et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol. 2003;92(4):463–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Turco MA. The integrity bare-metal stent made by continuous sinusoid technology. Expert Rev Med Devices. 2011;8(3):303–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Belardi JA, Albertal M. Integrity® coronary stent: a very limber bare-metal stent. Catheter Cardiovasc Interv. 2011;78(6):909.PubMedCrossRefGoogle Scholar
  18. 18.
    Ormiston JA, Webber B, Webster MW. Stent longitudinal integrity bench insights into a clinical problem. JACC Cardiovasc Interv. 2011;4(12):1310–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Hibbert B, O’Brien ER. Coronary stent fracture. CMAJ. 2011;183(11):E756.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Menown IB, Noad R, Garcia EJ, Meredith I. The platinum chromium element stent platform: from alloy, to design, to clinical practice. Adv Ther. 2010;27(3):129–41.PubMedCrossRefGoogle Scholar
  21. 21.
    Schmidt W, Lanzer P, Behrens P, Brandt-Wunderlich C, Schmitz K-P, Grabow N. Coronary bare metal and drug-eluting stents: if in trouble, select the best. In preparation.Google Scholar
  22. 22.
    Bonaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygard O, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:2602.CrossRefGoogle Scholar
  23. 23.
    Dumont FJ, Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1995;58(5):373–95.CrossRefGoogle Scholar
  24. 24.
    Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999;99(16):2164–70.PubMedCrossRefGoogle Scholar
  25. 25.
    Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a Sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346(23):1773–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Morice M-C, Serruys PW, Barragan P, Bode C, Van Es G-A, Stoll H-P, et al. Long-term clinical outcomes with Sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50(14):1299–304.PubMedCrossRefGoogle Scholar
  27. 27.
    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315–23.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM, et al. Two-year outcomes after Sirolimus-eluting stent implantation: results from the Sirolimus-eluting stent in de novo native coronary lesions (SIRIUS) trial. J Am Coll Cardiol. 2006;47(7):1350–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, et al. Five-year follow-up after Sirolimus-eluting stent implantation: results of the SIRIUS (Sirolimus-eluting stent in de-novo native coronary lesions) trial. J Am Coll Cardiol. 2009;53(17):1488–97.PubMedCrossRefGoogle Scholar
  30. 30.
    Schampaert E, Cohen EA, Schlüter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004;43(6):1110–5.PubMedCrossRefGoogle Scholar
  31. 31.
    Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003;362(9390):1093–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Schampaert E, Moses JW, Schofer J, Schlüter M, Gershlick AH, Cohen EA, et al. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent Thromboses. Am J Cardiol. 2006;98(1):36–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A. 1993;90(20):9552–6.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Liuzzo JP, Ambrose JA, Coppola JT. Sirolimus- and taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardiol. 2005;17(9):497–502.PubMedGoogle Scholar
  35. 35.
    Grube E, Silber S, Hauptmann KE, Buellesfeld L, Mueller R, Lim V, et al. Two-year-plus follow-up of a paclitaxel−eluting stent in de novo coronary narrowings (TAXUS I). Am J Cardiol. 2005;96(1):79–82.PubMedCrossRefGoogle Scholar
  36. 36.
    Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, et al. Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions - TAXUS I. Circulation. 2003;107(1):38–42.PubMedCrossRefGoogle Scholar
  37. 37.
    Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108(7):788–94.PubMedCrossRefGoogle Scholar
  38. 38.
    Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J. 2007;28(21):2578–82.PubMedCrossRefGoogle Scholar
  39. 39.
    Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294(10):1215–23.PubMedCrossRefGoogle Scholar
  40. 40.
    Stone GW, Ellis SG, Colombo A, Grube E, Popma JJ, Uchida T, et al. Long-term safety and efficacy of paclitaxel-eluting stents: final 5-year analysis from the TAXUS clinical trial program. J Am Coll Cardiol Intv. 2011;4(5):530–42.CrossRefGoogle Scholar
  41. 41.
    Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, et al. Results of the Sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation. 2011;123(24):2819–28.PubMedCrossRefGoogle Scholar
  42. 42.
    Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005;294(7):819–25.PubMedCrossRefGoogle Scholar
  43. 43.
    Schömig A, Dibra A, Windecker S, Mehilli J. Suárez de Lezo J, Kaiser C, et al. a meta-analysis of 16 randomized trials of Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol. 2007;50(14):1373–80.PubMedCrossRefGoogle Scholar
  44. 44.
    Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbæk H, et al. Analysis of 14 trials comparing Sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):1030–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing Sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356(10):989–97.PubMedCrossRefGoogle Scholar
  46. 46.
    Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice M-C, et al. Safety and efficacy of Sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356(10):998–1008.PubMedCrossRefGoogle Scholar
  47. 47.
    Farb A, Boam AB. Stent thrombosis Redux — the FDA perspective. N Engl J Med. 2007;356(10):984–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Burke SE, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev. 2006;58(3):437–46.PubMedCrossRefGoogle Scholar
  49. 49.
    Udipi K, Chen M, Cheng P, Jiang K, Judd D, Caceres A, et al. Development of a novel biocompatible polymer system for extended drug release in a next-generation drug-eluting stent. J Biomed Mater Res A. 2008;85A(4):1064–71.CrossRefGoogle Scholar
  50. 50.
    Kandzari DE. Development and performance of the zotarolimus-eluting Endeavor® coronary stent. Expert Rev Med Devices. 2010;7(4):449–59.PubMedCrossRefGoogle Scholar
  51. 51.
    Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Bonan R, et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. EuroIntervention. 2005;1(2):157–64.PubMedGoogle Scholar
  52. 52.
    Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II trial. Minerva Cardioangiol. 2007;55(1):1–18.PubMedGoogle Scholar
  53. 53.
    Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol. 2006;48(12):2440–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the Medtronic Endeavor drug [ABT-578] eluting coronary stent system versus the cypher Sirolimus-eluting coronary stent system in de novo native coronary artery lesions). JACC Cardiovasc Interv. 2011;4(5):543–50.PubMedCrossRefGoogle Scholar
  55. 55.
    Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, et al. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010;55(6):543–54.PubMedCrossRefGoogle Scholar
  56. 56.
    Wijns W, Steg PG, Mauri L, Kurowski V, Parikh K, Gao R, et al. Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent: 4-year results of the PROTECT randomized trial. Eur Heart J. 2014;35(40):2812–20.PubMedCrossRefGoogle Scholar
  57. 57.
    Udipi K, Melder RJ, Chen M, Cheng P, Hezi-Yamit A, Sullivan C, et al. The next generation Endeavor Resolute stent: role of the BioLinx polymer system. EuroIntervention. 2007;3(1):137–9.PubMedGoogle Scholar
  58. 58.
    Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention. 2007;3(1):50–3.PubMedGoogle Scholar
  59. 59.
    Meredith IT, Worthley SG, Whitbourn R, Walters D, McClean D, Ormiston J, et al. Long-term clinical outcomes with the next-generation Resolute stent system: a report of the two-year follow-up from the RESOLUTE clinical trial. EuroIntervention. 2010;5(6):692–7.PubMedCrossRefGoogle Scholar
  60. 60.
    Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363(2):136–46.PubMedCrossRefGoogle Scholar
  61. 61.
    von Birgelen C, Basalus MWZ, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JW, et al. A randomized controlled trial in second-generation Zotarolimus-eluting Resolute stents versus Everolimus-eluting Xience V stents in real-world PatientsThe TWENTE trial. J Am Coll Cardiol. 2012;59(15):1350–61.CrossRefGoogle Scholar
  62. 62.
    Di Santo P, Simard T, Ramirez FD, Pourdjabbar A, Harnett DT, Singh K, et al. Does stent strut design impact clinical outcomes: comparative safety and efficacy of Endeavor Resolute versus Resolute integrity zotarolimus-eluting stents. Clin Invest Med. 2015;38(5):E296–304.PubMedCrossRefGoogle Scholar
  63. 63.
    von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GAJ, Hautvast RWM, et al. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial. Lancet. 2014;383(9915):413–23.CrossRefGoogle Scholar
  64. 64.
    Sen H, Lam MK, Lowik MM, Danse PW, Jessurun GA, van Houwelingen KG, et al. Clinical events and patient-reported chest pain in all-comers treated with Resolute integrity and Promus element stents: 2-year follow-up of the DUTCH PEERS (DUrable polymer-based STent CHallenge of Promus ElemEnt versus ReSolute integrity) randomized trial (TWENTE II). JACC Cardiovasc Interv. 2015;8(7):889–99.PubMedCrossRefGoogle Scholar
  65. 65.
    Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36–42.PubMedCrossRefGoogle Scholar
  66. 66.
    Sedrani R, Cottens S, Kallen J, Schuler W. Chemical modification of rapamycin: the discovery of SDZ RAD. Transplant Proc. 1998;30(5):2192–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc. 1998;30(5):2200–3.PubMedCrossRefGoogle Scholar
  68. 68.
    Kukreja N, Onuma Y, Serruys PW. Xience V everolimus-eluting coronary stent. Expert Rev Med Devices. 2009;6(3):219–29.PubMedCrossRefGoogle Scholar
  69. 69.
    Woudstra P, Grundeken MJ, Kraak RP, MECJ H, Arkenbout EK, Baan J Jr, et al. Amsterdam investigator-initiated absorb strategy all-comers trial (AIDA trial): a clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: rationale and study design. Am Heart J. 2014;167(2):133–40.PubMedCrossRefGoogle Scholar
  70. 70.
    Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention. 2005;1(1):58–65.PubMedGoogle Scholar
  71. 71.
    Wiemer M, Serruys PW, Miquel-Hebert K, Neumann FJ, Piek JJ, Grube E, et al. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter Cardiovasc Interv. 2010;75(7):997–1003.PubMedGoogle Scholar
  72. 72.
    Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention. 2006;2(3):286–94.PubMedGoogle Scholar
  73. 73.
    Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial. Circ Cardiovasc Interv. 2009;2(4):339–47.PubMedCrossRefGoogle Scholar
  74. 74.
    Garg S, Serruys PW, Miquel-Hebert K. Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial. Catheter Cardiovasc Interv. 2011;77(7):1012–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299(16):1903–13.PubMedCrossRefGoogle Scholar
  76. 76.
    Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the clinical evaluation of the Xience V Everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III trial. Circulation. 2009;119(5):680–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663–74.PubMedCrossRefGoogle Scholar
  78. 78.
    Smits PC, Vlachojannis GJ, McFadden EP, Royaards KJ, Wassing J, Joesoef KS, et al. Final 5-year follow-up of a randomized controlled trial of Everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice: the COMPARE trial (a trial of Everolimus-eluting stents and paclitaxel stents for coronary revascularization in daily practice). JACC Cardiovasc Interv. 2015;8(9):1157–65.PubMedCrossRefGoogle Scholar
  79. 79.
    Jensen LO, Thayssen P, Maeng M, Christiansen EH, Ravkilde J, Hansen KN, et al. Three-year outcomes after revascularization with Everolimus- and Sirolimus-eluting stents from the SORT OUT IV trial. J Am Coll Cardiol Intv. 2014;7(8):840–8.CrossRefGoogle Scholar
  80. 80.
    de Waha A, Dibra A, Byrne RA, Ndrepepa G, Mehilli J, Fusaro M, et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2011;4(4):371–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Park KW, Chae I-H, Lim D-S, Han K-R, Yang H-M, Lee H-Y, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention the EXCELLENT (efficacy of Xience/Promus versus cypher to reduce late loss after stenting) randomized trial. J Am Coll Cardiol. 2011;58(18):1844–54.PubMedCrossRefGoogle Scholar
  82. 82.
    Piccolo R, Stefanini GG, Franzone A, Spitzer E, Blöchlinger S, Heg D, et al. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis. Circ Cardiovasc Interv. 2015;8:27-3427. DOI:  10.1161/CIRCINTERVENTIONS.114.002223 CrossRefGoogle Scholar
  83. 83.
    Stone GW, Teirstein PS, Meredith IT, Farah B, Dubois CL, Feldman RL, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial. J Am Coll Cardiol. 2011;57(16):1700–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Ormiston JA, Serruys PW. Bioabsorbable coronary stents. Circ Cardiovasc Interv. 2009;2(3):255–60.PubMedCrossRefGoogle Scholar
  85. 85.
    Tamai H, Igaki K, Kyo E, Kosuga K, Kawashima A, Matsui S, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102(4):399–404.PubMedCrossRefGoogle Scholar
  86. 86.
    Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20):1905–15.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Steinvil A, Rogers T, Torguson R, Waksman R. Overview of the 2016 U.S. Food and drug administration circulatory system devices advisory panel meeting on the absorb bioresorbable vascular scaffold system. JACC Cardiovasc Interv. 2016;9(17):1757–64.PubMedCrossRefGoogle Scholar
  88. 88.
    Puricel S, Cuculi F, Weissner M, Schmermund A, Jamshidi P, Nyffenegger T, et al. Bioresorbable coronary scaffold thrombosis multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors. J Am Coll Cardiol. 2016;67(8):921–31.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Haude M, Erbel R, Erne P, Verheye S, Degen H, Bose D, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet. 2013;381(9869):836–44.PubMedCrossRefGoogle Scholar
  90. 90.
    Haude M, Ince H, Abizaid A, Toelg R, Lemos PA, von Birgelen C, et al. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial. Lancet. 2016;387(10013):31–9.PubMedCrossRefGoogle Scholar
  91. 91.
    Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163–73.PubMedCrossRefGoogle Scholar
  92. 92.
    Hamon M, Niculescu R, Deleanu D, Dorobantu M, Weissman NJ, Waksman R. Clinical and angiographic experience with a third-generation drug-eluting Orsiro stent in the treatment of single de novo coronary artery lesions (BIOFLOW-I): a prospective, first-in-man study. EuroIntervention. 2013;8(9):1006–11.PubMedCrossRefGoogle Scholar
  93. 93.
    Waltenberger J, Brachmann J, van der Heyden J, Richardt G, Frobert O, Seige M, et al. Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry. EuroIntervention. 2016;11(10):1106–10.PubMedCrossRefGoogle Scholar
  94. 94.
    Windecker S, Haude M, Neumann F-J, Stangl K, Witzenbichler B, Slagboom T, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent. Results of the Randomized BIOFLOW-II Trial. Circ Cardiovasc Interv. 2015;8(2):e001441.PubMedCrossRefGoogle Scholar
  95. 95.
    Steigen TK, Maeng M, Wiseth R, Erglis A, Kumsars I, Narbute I, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions. The Nordic bifurcation study. Circulation. 2006;114(18):1955–61.PubMedCrossRefGoogle Scholar
  96. 96.
    Myler RK, Shaw RE, Stertzer SH, Hecht HS, Ryan C, Rosenblum J, et al. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol. 1992;19(7):1641–52.PubMedCrossRefGoogle Scholar
  97. 97.
    Latib A, Colombo A. Bifurcation disease: what do we know, what should we do? JACC Cardiovasc Interv. 2008;1(3):218–26.PubMedCrossRefGoogle Scholar
  98. 98.
    Leesar MA, Hakeem A, Azarnoush K, Thuesen L. Coronary bifurcation lesions: present status and future perspectives. Int J Cardiol. 2015;187:48–57.PubMedCrossRefGoogle Scholar
  99. 99.
    Pan M, de Lezo JS, Medina A, Romero M, Segura J, Pavlovic D, et al. Rapamycin-eluting stents for the treatment of bifurcated coronary lesions: a randomized comparison of a simple versus complex strategy. Am Heart J. 2004;148(5):857–64.PubMedCrossRefGoogle Scholar
  100. 100.
    Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109(10):1244–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Ormiston JA, Lefevre T, Grube E, Allocco DJ, Dawkins KD. First human use of the TAXUS petal paclitaxel-eluting bifurcation stent. EuroIntervention. 2010;6(1):46–53.PubMedCrossRefGoogle Scholar
  102. 102.
    Pillai AA, Jayaraman B. Dedicated bifurcation stents. Indian Heart J. 2012;64(2):187–95.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Généreux P, Kumsars I, Lesiak M, Kini A, Fontos G, Slagboom T, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. J Am Coll Cardiol. 2015;65(6):533–43.PubMedCrossRefGoogle Scholar
  104. 104.
    Lassen JF, Holm NR, Stankovic G, Lefevre T, Chieffo A, Hildick-Smith D, et al. Percutaneous coronary intervention for coronary bifurcation disease: consensus from the first 10 years of the European bifurcation Club meetings. EuroIntervention. 2014;10(5):545–60.PubMedCrossRefGoogle Scholar
  105. 105.
    Jamshidi P, Mahmoody K, Erne P. Covered stents: a review. Int J Cardiol. 2008;130(3):310–8.PubMedCrossRefGoogle Scholar
  106. 106.
    Stefanadis C, Tsiamis E, Vlachopoulos C, Toutouzas K, Stratos C, Kallikazaros I, et al. Autologous vein graft-coated stents for the treatment of thrombus-containing coronary artery lesions. Catheter Cardiovasc Diagn. 1997;40(2):217–22.CrossRefGoogle Scholar
  107. 107.
    Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, Cernigliaro C, et al. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the randomized evaluation of polytetrafluoroethylene COVERed stent in saphenous vein grafts (RECOVERS) trial. Circulation. 2003;108(1):37–42.PubMedCrossRefGoogle Scholar
  108. 108.
    Keeley EC, Velez CA, O’Neill WW, Safian RD. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol. 2001;38(3):659–65.PubMedCrossRefGoogle Scholar
  109. 109.
    Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105(11):1285–90.PubMedGoogle Scholar
  110. 110.
    Turco MA, Buchbinder M, Popma JJ, Weissman NJ, Mann T, Doucet S, et al. Pivotal, randomized U.S. study of the Symbiot™ covered stent system in patients with saphenous vein graft disease: eight-month angiographic and clinical results from the Symbiot III trial. Catheter Cardiovasc Interv. 2006;68(3):379–88.PubMedCrossRefGoogle Scholar
  111. 111.
    Stone GW, Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Cristea E, et al. 5-year follow-up of polytetrafluoroethylene-covered stents compared with bare-metal stents in aortocoronary saphenous vein grafts the randomized BARRICADE (barrier approach to restenosis: restrict intima to curtail adverse events) trial. JACC Cardiovasc Interv. 2011;4(3):300–9.PubMedCrossRefGoogle Scholar
  112. 112.
    Schachinger V, Hamm CW, Munzel T, Haude M, Baldus S, Grube E, et al. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol. 2003;42(8):1360–9.PubMedCrossRefGoogle Scholar
  113. 113.
    Briguori C, De Gregorio J, Nishida T, Adamian M, Albiero R, Tucci G, et al. Polytetrafluoroethylene-covered stent for the treatment of narrowings in aorticocoronary saphenous vein grafts. Am J Cardiol. 2000;86(3):343–6.PubMedCrossRefGoogle Scholar
  114. 114.
    Dogu Kilic I, Fabris E, Serdoz R, Caiazzo G, Foin N, Abou-Sherif S, et al. Coronary covered stents. EuroIntervention. 2016;12(10):1288–95.CrossRefGoogle Scholar
  115. 115.
    Briguori C, Nishida T, Anzuini A, Di Mario C, Grube E, Colombo A. Emergency polytetrafluoroethylene-covered stent implantation to treat coronary ruptures. Circulation. 2000;102(25):3028–31.PubMedCrossRefGoogle Scholar
  116. 116.
    Jokhi PP, McKenzie DB, O'Kane P. Use of a novel pericardial covered stent to seal an iatrogenic coronary perforation. J Invasive Cardiol. 2009;21(10):E187–90.PubMedGoogle Scholar
  117. 117.
    Romaguera R, Waksman R. Covered stents for coronary perforations: is there enough evidence? Catheter Cardiovasc Interv. 2011;78(2):246–53.PubMedCrossRefGoogle Scholar
  118. 118.
    Albiero R, Nishida T, Corvaja N, Vaghetti M, Di Mario C, Colombo A. Left internal mammary artery graft perforation repair using polytetrafluoroethylene-covered stents. Catheter Cardiovasc Interv. 2000;51(1):78–82.PubMedCrossRefGoogle Scholar
  119. 119.
    Colon PJ 3rd, Ramee SR, Mulingtapang R, Pridjian A, Bhatia D, Collins TJ. Percutaneous bailout therapy of a perforated vein graft using a stent-autologous vein patch. Catheter Cardiovasc Diagn. 1996;38(2):175–8.CrossRefGoogle Scholar
  120. 120.
    Bonello L, Com O, Gaubert JY, Sbraggia P, Paganelli F. Covered stent for closure of symptomatic plexus-like coronary fistula. Int J Cardiol. 2006;109(3):408–10.PubMedCrossRefGoogle Scholar
  121. 121.
    Ahn Y, Park OY, Jeong MH. Combined membrane covered and uncovered stents for coronary arteriovenous fistula associated with atherosclerotic plaque in a patient with acute myocardial infarction. Heart. 2004;90(2):150.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Harandi S, Johnston SB, Wood RE, Roberts WC. Operative therapy of coronary arterial aneurysm. Am J Cardiol. 1999;83(8):1290–3.PubMedCrossRefGoogle Scholar
  123. 123.
    Briguori C, Sarais C, Sivieri G, Takagi T, Di Mario C, Colombo A. Polytetrafluoroethylene-covered stent and coronary artery aneurysms. Catheter Cardiovasc Interv. 2002;55(3):326–30.PubMedCrossRefGoogle Scholar
  124. 124.
    Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–7.PubMedCrossRefPubMedCentralGoogle Scholar
  125. 125.
    Hibbert B, Olsen S, O'Brien E. Involvement of progenitor cells in vascular repair. Trends Cardiovasc Med. 2003;13(8):322–6.PubMedCrossRefGoogle Scholar
  126. 126.
    Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (healthy endothelial accelerated lining inhibits Neointimal growth-first in man) registry. J Am Coll Cardiol. 2005;45(10):1574–9.PubMedCrossRefGoogle Scholar
  127. 127.
    Co M, Tay E, Lee CH, Poh KK, Low A, Lim J, et al. Use of endothelial progenitor cell capture stent (Genous bio-engineered R stent) during primary percutaneous coronary intervention in acute myocardial infarction: intermediate- to long-term clinical follow-up. Am Heart J. 2008;155(1):128–32.PubMedCrossRefGoogle Scholar
  128. 128.
    Beijk MA, Klomp M, Verouden NJ, van Geloven N, Koch KT, Henriques JP, et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J. 2010;31(9):1055–64.PubMedCrossRefGoogle Scholar
  129. 129.
    Nakazawa G, Granada JF, Alviar CL, Tellez A, Kaluza GL, Guilhermier MY, et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv. 2010;3(1):68–75.PubMedCrossRefGoogle Scholar
  130. 130.
    Woudstra P, de Winter RJ, Beijk MA. Next-generation DES: the COMBO dual therapy stent with Genous endothelial progenitor capturing technology and an abluminal sirolimus matrix. Expert Rev Med Devices. 2014;11(2):121–35.PubMedCrossRefGoogle Scholar
  131. 131.
    Woudstra P, Kalkman DN, den Heijer P, Menown IB, Erglis A, Suryapranata H, et al. 1-year results of the REMEDEE registry: clinical outcomes after deployment of the Abluminal sirolimus-coated bioengineered (Combo) stent in a multicenter, prospective all-comers registry. JACC Cardiovasc Interv. 2016;9(11):1127–34.PubMedCrossRefGoogle Scholar
  132. 132.
    George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A, et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol. 2003;23(12):e57–60.PubMedCrossRefGoogle Scholar
  133. 133.
    Hibbert B, Ma X, Pourdjabbar A, Holm E, Rayner K, Chen YX, et al. Inhibition of endothelial progenitor cell glycogen synthase kinase-3beta results in attenuated neointima formation and enhanced re-endothelialization after arterial injury. Cardiovasc Res. 2009;83(1):16–23.PubMedCrossRefGoogle Scholar
  134. 134.
    Ma X, Hibbert B, Dhaliwal B, Seibert T, Chen YX, Zhao X, et al. Delayed re-endothelialization with rapamycin-coated stents is rescued by the addition of a glycogen synthase kinase-3beta inhibitor. Cardiovasc Res. 2010;86(2):338–45.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Trevor Simard
    • 1
    • 2
    Email author
  • Juan J. Russo
    • 1
  • Edward R. O’Brien
    • 3
  • Benjamin Hibbert
    • 1
    • 2
  1. 1.CAPITAL Research Group, Division of CardiologyUniversity of Ottawa Heart InstituteOttawaCanada
  2. 2.Department of Cellular and Molecular MedicineUniversity of OttawaOttawaCanada
  3. 3.Division of CardiologyLibin Cardiovascular Institute of Alberta, University of CalgaryCalgaryCanada

Personalised recommendations